Proudly presenting our Phase 1/1b, First-in-Human, multi-part study of DF6215, an engineered IL-2Rα-active agonist for advanced solid tumors, in the Developmental Therapeutics-Immunotherapy poster session at American Society of Clinical Oncology (ASCO) with Benedito A. Carneiro, MD, MS, Brown University #ASCO24
Interesting!
Chief Medical Officer | Board Member | Strategic Experienced Drug Developer | Hematology and Oncology
3moWell done Mary (and team)!